Compounds > 4-amino-2-methoxypyrimidine
Page last updated: 2024-11-07

4-amino-2-methoxypyrimidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-amino-2-methoxypyrimidine: recognized by E. coli DNA repair enzymes; shown to exhibit strong miscoding properties [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-O-methylcytosine : Pyrimidine substituted with a methoxy group at position C-2 and an amine group at C-4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID160679
CHEBI ID70854
SCHEMBL ID331710
MeSH IDM0056094

Synonyms (41)

Synonym
2-methoxy-pyrimidin-4-ylamine
ENAMINE_000557
3289-47-2
4-pyrimidinamine, 2-methoxy- (9ci)
HMS1395J07
2-methoxypyrimidin-4-amine
AKOS001012915
A5879
4-pyrimidinamine, 2-methoxy-
4-amino-2-methoxypyrimidine
o(2)medc
o-2-methylcytosine
FT-0645410
PS-3920
AM20090489
2-methoxy-4-pyrimidinamine
PB29013
2-o-methylcytosine
CHEBI:70854
SCHEMBL331710
2-methoxypyrimidine-4-amine
2-(methyloxy)-4-pyrimidinamine
pyrimidine, 4-amino-2-methoxy-
2-methoxy-4-pyrimidinamine #
2-methoxy-4-aminopyrimidine
AC-31863
mfcd00128201
STL451542
J-509883
4-amino-2-methoxypyrimidine, aldrichcpr
DTXSID30186543
CS-0006060
SY029964
Q27139147
4-pyrimidinamine,2-methoxy-(9ci)
HY-69014
BCP23476
2-pyrimidinamine,4-methoxy-(9ci)
EN300-130985
PD157959
Z56773387
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
aminopyrimidineA member of the class of pyrimidines that is pyrimidine substituted by at least one amino group and its derivatives.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
methylcytosine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (40.00)18.7374
1990's1 (20.00)18.2507
2000's0 (0.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.42 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
cytosine
[no description available]		2.8940aminopyrimidine;
pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
thymine
[no description available]		1.9610pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite
uridine
[no description available]		1.9810uridinesdrug metabolite;
fundamental metabolite;
human metabolite
o-4-methylthymine
O(4)-methylthymine : A methylthymine in which the methyl group is located at the O4-position.		1.9610aromatic ether;
methylthymine		human metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610